Doxycycline as a potential partner of COVID-19 therapies
Alexandre Malek, Bruno Granwehr, Dimitrios P. Kontoyiannis
Abstract
Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.
Topics & Concepts
DoxycyclineMedicineRepurposingCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineCytokine storm2019-20 coronavirus outbreakCoronavirusDrug repositioningPneumoniaDiseasePharmacologyVirologyInfectious disease (medical specialty)DrugInternal medicineAntibioticsOutbreakBiologyMicrobiologyEcologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCalcium signaling and nucleotide metabolism